RUNX1 and acute myeloid leukemia: These fusions, such as RUNX1-RUNX1T1 and KMT2A rearrangements, are key diagnostic markers and are incorporated into contemporary AML classification systems, including WHO, ELN, and ICC, for risk stratification and treatment guidance.